<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Cenexis Bio - Confidential Briefing</title>
    <style>
        /* --- RESET & BASICS --- */
        * { box-sizing: border-box; margin: 0; padding: 0; }
        body {
            background-color: #060606;
            color: #d9d9d9;
            font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif;
            line-height: 1.6;
            padding: 40px;
            max-width: 900px;
            margin: 0 auto;
        }

        /* --- TYPOGRAPHY --- */
        h1, h2, h3 { color: #ffffff; line-height: 1.2; }
        h1 { font-size: 42px; margin-bottom: 20px; }
        h2 { font-size: 30px; margin-top: 40px; margin-bottom: 15px; color: #d9d9d9; }
        h3 { font-size: 18px; color: #ffffff; margin-top: 20px; margin-bottom: 5px; }
        
        p { margin-bottom: 15px; color: #757575; font-size: 14px; }
        strong { color: #d9d9d9; }
        
        /* --- UTILITY COLORS --- */
        .text-red { color: #c61a24; }
        .text-green { color: #2cc55e; }
        .text-white { color: #ffffff; }
        
        /* --- HEADER & NAV --- */
        header {
            display: flex;
            justify-content: space-between;
            align-items: center;
            border-bottom: 1px solid #333;
            padding-bottom: 20px;
            margin-bottom: 40px;
        }
        .brand { font-size: 18px; font-weight: bold; letter-spacing: 1px; }
        nav a {
            color: #757575;
            text-decoration: none;
            margin-left: 20px;
            font-size: 12px;
            text-transform: uppercase;
        }
        nav a:hover { color: #c61a24; }

        /* --- HERO SECTION --- */
        .hero { margin-bottom: 60px; }
        .confidential-tag {
            color: #c61a24;
            font-size: 11px;
            letter-spacing: 1px;
            font-weight: bold;
            margin-bottom: 15px;
            display: block;
        }
        .hero-subtitle { font-size: 16px; color: #757575; max-width: 600px; }
        .cta-arrow { color: #c61a24; margin-top: 20px; display: block; font-weight: bold; text-decoration: none;}

        /* --- LISTS --- */
        ul { list-style: none; margin-bottom: 20px; }
        li { margin-bottom: 8px; padding-left: 15px; border-left: 2px solid #333; color: #d9d9d9; font-size: 13px; }

        /* --- COMPARISON (Status Quo vs Solution) --- */
        .comparison-grid {
            display: grid;
            grid-template-columns: 1fr 1fr;
            gap: 40px;
            margin: 40px 0;
            border-top: 1px solid #333;
            border-bottom: 1px solid #333;
            padding: 30px 0;
        }
        .status-block h4 { font-size: 12px; letter-spacing: 1px; margin-bottom: 10px; }
        
        /* --- STATS GRID --- */
        .stats-grid {
            display: grid;
            grid-template-columns: repeat(4, 1fr);
            gap: 20px;
            text-align: center;
            margin: 40px 0;
        }
        .stat-item h3 { color: #c61a24; font-size: 24px; margin-bottom: 5px; }
        .stat-item p { font-size: 11px; color: #757575; background: #0f0f0f; padding: 10px; border-radius: 4px; }

        /* --- TEAM GRID --- */
        .team-grid {
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 30px;
            margin-top: 20px;
        }
        .team-member { background: #0f0f0f; padding: 20px; border-radius: 4px; }
        .team-role { color: #c61a24; font-size: 11px; text-transform: uppercase; margin-bottom: 8px; display: block; }

        /* --- FOOTER & FORM --- */
        .footer {
            margin-top: 80px;
            padding-top: 40px;
            border-top: 1px solid #333;
            text-align: center;
        }
        .contact-box {
            background: #0f0f0f;
            padding: 30px;
            max-width: 500px;
            margin: 0 auto 40px auto;
            text-align: left;
        }
        .contact-box input, .contact-box select {
            width: 100%;
            background: #000;
            border: 1px solid #333;
            color: #fff;
            padding: 10px;
            margin-bottom: 10px;
        }
        .btn-request {
            background: #c61a24;
            color: #fff;
            border: none;
            padding: 10px 20px;
            width: 100%;
            cursor: pointer;
            font-weight: bold;
        }
        .contact-links a { color: #757575; text-decoration: none; display: block; margin-bottom: 5px; }
        .contact-links a:hover { color: #fff; }

    </style>
</head>
<body>

    <header>
        <div class="brand">CENEXIS BIO</div>
        <nav>
            <a href="#gap">The Gap</a>
            <a href="#solution">Solution</a>
            <a href="#status">Status</a>
            <a href="#team">Team</a>
            <a href="#contact" style="color: #c61a24;">Request Access</a>
        </nav>
    </header>

    <section class="hero">
        <span class="confidential-tag">CONFIDENTIAL BRIEFING // [LLNL-02 / CX-101]</span>
        <h1>Beyond Survival.<br><span style="opacity: 0.5;">Protecting the Cognitive Edge.</span></h1>
        <p class="hero-subtitle">Developing the next generation of nerve agent antidotes. The first therapeutic capability was designed to preserve both life and brain function.</p>
        <a href="#" class="cta-arrow">VIEW THE MISSION ↓</a>
    </section>

    <hr style="border: 0; border-top: 1px solid #333; margin: 40px 0;">

    <section id="gap">
        <h2>The Status Quo is Grossly Inadequate</h2>
        <p>Nerve agents—including Sarin, VX, and Novichok—remain a credible and evolving threat in asymmetric conflicts. Current medical countermeasures (legacy oximes) save lives; they were designed for survival, not neuroprotection.</p>
        <ul>
            <li><strong>The Barrier:</strong> Existing antidotes possess limited CNS penetration.</li>
            <li><strong>The Consequence:</strong> Survivors often suffer rapid, irreversible neurologic damage.</li>
            <li><strong>The Gap:</strong> There are currently no FDA-approved CNS-protective antidotes.</li>
        </ul>
        <blockquote style="border-left: 3px solid #c61a24; padding-left: 15px; font-style: italic; color: #d9d9d9; margin: 20px 0;">
            "Current countermeasures keep the victim alive but leave them unprotected from longterm neurologic injury."
        </blockquote>
    </section>

    <section class="comparison-grid" id="solution">
        <div class="status-block">
            <h4 class="text-red">BLOOD-BRAIN BARRIER: BLOCKED</h4>
            <p>Legacy solutions cannot reach the brain effectively to stop central seizure activity.</p>
        </div>
        <div class="status-block">
            <h4 class="text-green">TARGET: PENETRATED</h4>
            <h3 class="text-green" style="margin-top: 0;">LLNL-02 / CX-101</h3>
            <p>The first nerve-agent antidote capable of crossing the blood-brain barrier to preserve neurologic function.</p>
        </div>
    </section>

    <section>
        <h2>True CNS Defense: LLNL-02 / CX-101</h2>
        <p>Developed at Lawrence Livermore National Laboratory (LLNL), LLNL-02 / CX-101 is engineered to replace the 60-year-old agent currently in the Strategic National Stockpile.</p>
        
        <div class="team-grid"> <div>
                <h3>First-in-Class CNS Penetration</h3>
                <p>Developed by LLNL research scientists as the first nerve-agent antidote capable of crossing the blood-brain barrier.</p>
            </div>
            <div>
                <h3>5x Longer Exposure</h3>
                <p>Demonstrates approximately 5x longer durable systemic exposure than current standard-of-care antidotes.</p>
            </div>
            <div>
                <h3>Drop-In Ready</h3>
                <p>Designed as a superior replacement for legacy oximes in existing autoinjector platforms—not just an adjunct.</p>
            </div>
        </div>
    </section>

    <section id="status">
        <h2>De-Risked Execution</h2>
        <p>A mandated execution program aligned with national security requirements.</p>
        <div class="stats-grid">
            <div class="stat-item">
                <h3>$7M</h3>
                <p>Non-Dilutive Gov Investment</p>
            </div>
            <div class="stat-item">
                <h3>LLNL</h3>
                <p>Developed at Lawrence Livermore National Lab</p>
            </div>
            <div class="stat-item">
                <h3>FDA</h3>
                <p>Animal Rule Pathway (No Human Efficacy Trials)</p>
            </div>
            <div class="stat-item">
                <h3>US GOV</h3>
                <p>Guaranteed Buyer & Validator</p>
            </div>
        </div>
    </section>

    <section id="team">
        <h2>The Architects</h2>
        <div class="team-grid">
            <div class="team-member">
                <h3>Ray Stevens, MBA</h3>
                <span class="team-role">CEO</span>
                <p>Expertise: Program execution & leadership.</p>
            </div>
            <div class="team-member">
                <h3>Stewart McCallum, MD FACS</h3>
                <span class="team-role">CMO</span>
                <p>20 + years of global development & regulatory expertise.</p>
            </div>
            <div class="team-member">
                <h3>Dale Bennyhoff </h3>
                <span class="team-role">Head, CMC & Quality</span>
                <p>25+ years in CMC, scale-up, and GMP readiness.</p>
            </div>
            <div class="team-member">
                <h3>Bryan Katz, MBA</h3>
                <span class="team-role">CBO / CFO</span>
                <p>26-year pharma leader & US Marine.</p>
            </div>
        </div>
    </section>

    <section class="footer">
        <h2>Restricted Access</h2>
        <p style="margin-bottom: 30px;">Cenexis Bio is currently executing a government-aligned Series A roadmap. Detailed data rooms are available only to authorized parties.</p>
        
        <div class="contact-box">
            <p class="text-white" style="margin-bottom: 10px;">Request Briefing</p>
            <input type="text" placeholder="Full Name">
            <input type="text" placeholder="Organization / Fund">
            <input type="email" placeholder="Official Email">
            <select>
                <option>Investor Relations</option>
                <option>Strategic Partnership (DoD/BARDA)</option>
                <option>Media</option>
            </select>
            <button class="btn-request">REQUEST BRIEFING</button>
        </div>

        <div class="contact-links">
            <p>Direct Contact:</p>
            <a href="mailto:info@cenexisbio.com">Ray Stevens (CEO) – info@cenexisbio.com</a>
            <a href="mailto:info@cenexisbio.com">Bryan Katz (CBO) – info@cenexisbio.com</a>
        </div>
        
        <p style="margin-top: 40px; font-size: 10px; opacity: 0.5;">© 2026 Cenexis Bio. All Rights Reserved.</p>
    </section>

</body>
</html>
